ClinicalTrials.gg
CompletedNCT00761774Updated Jul 11, 2018Results posted

An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam

A Phase 3 interventional study of Brivaracetam in Epilepsy, sponsored by UCB Pharma. Completed at 58 sites in 11 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2018-07-11.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
108
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.

Enrollment
14th of 34
108 · median 94
Started
2008
with 3 others
Phase 3
21 of 34
1 open now
Registered
14th of 34
by date
Lead sponsor
13 of 34
UCB Pharma

Among the 34 studies testing brivaracetam in Epilepsy, this one is the 14th largest by enrollment, is one of 4 that started in 2008, is one of 21 in phase 3, and was the 14th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About brivaracetam

brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing brivaracetam in Epilepsy, or all of them as a file.
02

Study summary

The Sponsor wishes to develop brivaracetam as an anti-epileptic treatment in subjects 16 years and older with epilepsy. This study permits continued access to treatment for subjects who participated in a previous epilepsy study. The study will explore the long-term safety and efficacy of brivaracetam.

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Epilepsy
  • Monotherapy
  • Partial Onset Seizures
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with epilepsy who participated in previous brivaracetam trials which allow access to the present trial.
  • Subjects from whom the Investigator believes a reasonable potential benefit from the long-term administration of brivaracetam may be expected.

Exclusion criteria

Exclusion Criteria:

  • Severe medical, neurological and psychiatric disorders, including current suicidal ideation or behaviour, or laboratory values which may have an impact on the safety of the subject, as determined by the investigator.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
108 participants (actual)

Study arms

  • Experimental
    Brivaracetam

    Brivaracetam at flexible dosing up to 200mg /day

    Drug: Brivaracetam

Interventions

  • Subjects will begin at a recommended dose of Brivaracetam 100 mg/day. Subjects will continue treatment at a dose up to a maximum of 200 mg/day with a twice per day administration. Up- and down-titration steps may be performed in steps of a maximum of 50 mg/day on a weekly basis. Full down-titration should include a one week step on 20 mg/day. The study medication will come in 10 mg and 25 mg tablet strengths.

    Also known as: ucb 34714

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects With at Least One Treatment-emergent Adverse Event (TEAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (up to 9 Years)

    Treatment-emergent Adverse events (TEAE) are any untoward medical occurrences in a subject during administered study treatment, whether or not these events are related to study treatment.

    Time frame: During the Evaluation Period (up to 9 years)

  2. Percentage of Subjects Who Withdrew Due to Adverse Event (AE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (up to 9 Years)

    Adverse Events (AE) are any untoward medical occurrences in a subject during administered study treatment, whether or not these events are related to study treatment.

    Time frame: During the Evaluation Period (up to 9 years)

  3. Percentage of Subjects With a Serious Adverse Event (SAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (up to 9 Years)

    An SAE was any untoward medical occurrence that, at any dose resulted in death, was life threatening, required in-subject hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was a congenital anomaly/birth defect.

    Time frame: During the Evaluation Period (up to 9 years)

Secondary outcomes

  1. Percentage of Subjects on Continuous Brivaracetam Monotherapy for at Least 3 Months of the Evaluation Period (up to 9 Years)

    BRV monotherapy is defined as continuous treatment with BRV only (ie, no treatment with another anti-epileptic drug (AED)). Use of rescue AED for a duration of no more than 2 consecutive days will not disqualify a subject from being defined as on continuous monotherapy provided the use of rescue AED does not exceed more than 1 time per week.

    Time frame: During the Evaluation Period (up to 9 years)

  2. Percentage of Subjects on Continuous Brivaracetam Monotherapy for at Least 6 Months, of the Evaluation Period (up to 9 Years)

    BRV monotherapy is defined as continuous treatment with BRV only (ie, no treatment with another anti-epileptic drug (AED)). Use of rescue AED for a duration of no more than 2 consecutive days will not disqualify a subject from being defined as on continuous monotherapy provided the use of rescue AED does not exceed more than 1 time per week.

    Time frame: During the Evaluation Period (up to 9 years)

  3. Percentage of Subjects on Continuous Brivaracetam Monotherapy for at Least 12 Months of the Evaluation Period (up to 9 Years)

    BRV monotherapy is defined as continuous treatment with BRV only (ie, no treatment with another anti-epileptic drug (AED)). Use of rescue AED for a duration of no more than 2 consecutive days will not disqualify a subject from being defined as on continuous monotherapy provided the use of rescue AED does not exceed more than 1 time per week.

    Time frame: During the Evaluation Period (up to 9 years)

07

Results

Posted Apr 23, 2018

Participant flow

The study started to enroll patients in November 2008 and concluded in March 2017.

Participant flow — Overall Study
MilestoneBrivaracetam
Started108
Completed29
Not completed79
Withdrew: Adverse event17
Withdrew: Lack of efficacy37
Withdrew: Lost to follow-up2
Withdrew: Withdrawal by subject9
Withdrew: Non-compliance4
Withdrew: End of study2
Withdrew: Reclassification of seizures1
Withdrew: Medical decision to read susar reports1
Withdrew: Sponsor decision1
Withdrew: Investigator clinical judgement1
Withdrew: Patient moved out of study area1
Withdrew: Coordinator leaving site1
Withdrew: Subject ip non-compliance1
Withdrew: Ip stopped by hospital physician1

Outcome measures

PrimaryPercentage of Subjects With at Least One Treatment-emergent Adverse Event (TEAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (up to 9 Years)

Treatment-emergent Adverse events (TEAE) are any untoward medical occurrences in a subject during administered study treatment, whether or not these events are related to study treatment.

Time frame:
During the Evaluation Period (up to 9 years)
Reported as:
Number · percentage of participants
Percentage of Subjects With at Least One Treatment-emergent Adverse Event (TEAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (up to 9 Years)
percentage of participantsBrivaracetam (SS)
Percentage of Subjects With at Least One Treatment-emergent Adverse Event (TEAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (up to 9 Years)90.7
PrimaryPercentage of Subjects Who Withdrew Due to Adverse Event (AE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (up to 9 Years)

Adverse Events (AE) are any untoward medical occurrences in a subject during administered study treatment, whether or not these events are related to study treatment.

Time frame:
During the Evaluation Period (up to 9 years)
Reported as:
Number · percentage of participants
Percentage of Subjects Who Withdrew Due to Adverse Event (AE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (up to 9 Years)
percentage of participantsBrivaracetam (SS)
Percentage of Subjects Who Withdrew Due to Adverse Event (AE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (up to 9 Years)15.7
PrimaryPercentage of Subjects With a Serious Adverse Event (SAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (up to 9 Years)

An SAE was any untoward medical occurrence that, at any dose resulted in death, was life threatening, required in-subject hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was a congenital anomaly/birth defect.

Time frame:
During the Evaluation Period (up to 9 years)
Reported as:
Number · percentage of participants
Percentage of Subjects With a Serious Adverse Event (SAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (up to 9 Years)
percentage of participantsBrivaracetam (SS)
Percentage of Subjects With a Serious Adverse Event (SAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (up to 9 Years)24.1
SecondaryPercentage of Subjects on Continuous Brivaracetam Monotherapy for at Least 3 Months of the Evaluation Period (up to 9 Years)

BRV monotherapy is defined as continuous treatment with BRV only (ie, no treatment with another anti-epileptic drug (AED)). Use of rescue AED for a duration of no more than 2 consecutive days will not disqualify a subject from being defined as on continuous monotherapy provided the use of rescue AED does not exceed more than 1 time per week.

Time frame:
During the Evaluation Period (up to 9 years)
Reported as:
Number · percentage of participants
Percentage of Subjects on Continuous Brivaracetam Monotherapy for at Least 3 Months of the Evaluation Period (up to 9 Years)
percentage of participantsBrivaracetam (ES)
Percentage of Subjects on Continuous Brivaracetam Monotherapy for at Least 3 Months of the Evaluation Period (up to 9 Years)38.89
SecondaryPercentage of Subjects on Continuous Brivaracetam Monotherapy for at Least 6 Months, of the Evaluation Period (up to 9 Years)

BRV monotherapy is defined as continuous treatment with BRV only (ie, no treatment with another anti-epileptic drug (AED)). Use of rescue AED for a duration of no more than 2 consecutive days will not disqualify a subject from being defined as on continuous monotherapy provided the use of rescue AED does not exceed more than 1 time per week.

Time frame:
During the Evaluation Period (up to 9 years)
Reported as:
Number · percentage of participants
Percentage of Subjects on Continuous Brivaracetam Monotherapy for at Least 6 Months, of the Evaluation Period (up to 9 Years)
percentage of participantsBrivaracetam (ES)
Percentage of Subjects on Continuous Brivaracetam Monotherapy for at Least 6 Months, of the Evaluation Period (up to 9 Years)32.41
SecondaryPercentage of Subjects on Continuous Brivaracetam Monotherapy for at Least 12 Months of the Evaluation Period (up to 9 Years)

BRV monotherapy is defined as continuous treatment with BRV only (ie, no treatment with another anti-epileptic drug (AED)). Use of rescue AED for a duration of no more than 2 consecutive days will not disqualify a subject from being defined as on continuous monotherapy provided the use of rescue AED does not exceed more than 1 time per week.

Time frame:
During the Evaluation Period (up to 9 years)
Reported as:
Number · percentage of participants
Percentage of Subjects on Continuous Brivaracetam Monotherapy for at Least 12 Months of the Evaluation Period (up to 9 Years)
percentage of participantsBrivaracetam (ES)
Percentage of Subjects on Continuous Brivaracetam Monotherapy for at Least 12 Months of the Evaluation Period (up to 9 Years)25

Adverse events

Collected over Adverse events were collected throughout the study (up to 9 years).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brivaracetam (SS)1/108 (0.9%)26/108 (24.1%)81/108 (75%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventBrivaracetam (SS)
ConvulsionNervous system disorders5/108
Angina pectorisCardiac disorders3/108
Atrial fibrillationCardiac disorders2/108
CholelithiasisHepatobiliary disorders2/108
ContusionInjury, poisoning and procedural complications2/108
Grand mal convulsionNervous system disorders2/108
Cardiac failure congestiveCardiac disorders1/108
Abdominal painGastrointestinal disorders1/108
Pancreatitis acuteGastrointestinal disorders1/108
VomitingGastrointestinal disorders1/108
Most frequent other events
Showing 10 of 29
Most frequent other events
EventBrivaracetam (SS)
NasopharyngitisInfections and infestations19/108
DepressionPsychiatric disorders18/108
FatigueGeneral disorders17/108
ConvulsionNervous system disorders17/108
FallInjury, poisoning and procedural complications15/108
HeadacheNervous system disorders15/108
AnxietyPsychiatric disorders15/108
InsomniaPsychiatric disorders15/108
DizzinessNervous system disorders14/108
RashSkin and subcutaneous tissue disorders13/108

Baseline characteristics

Baseline Characteristics refer to the Safety Set which consisted of all subjects who received at least 1 dose of study medication.

Age, Categorical
Age, Categorical(Participants)Brivaracetam
<=18 years0
Between 18 and 65 years103
>=65 years5
Age, Continuous
Age, Continuous(years)Brivaracetam
Mean40.8 ± 13
Sex: Female, Male
Sex: Female, Male(Participants)Brivaracetam
Female56
Male52
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Brivaracetam
Black or African American7
White97
Other/Mixed4
08

Study locations

58 sites
  • 304
    Phoenix, Arizona, United States
  • 281
    Fresno, California, United States
  • 288
    Pasadena, California, United States
  • 240
    Riverside, California, United States
  • 245
    Sacramento, California, United States
  • 285
    Peoria, Illinois, United States
  • 224
    Indianapolis, Indiana, United States
  • 266
    Lexington, Kentucky, United States
  • 231
    Waldorf, Maryland, United States
  • 278
    Burlington, Massachusetts, United States
  • 270
    New York, New York, United States
  • 284
    Hickory, North Carolina, United States
  • 241
    Columbus, Ohio, United States
  • 265
    Oklahoma City, Oklahoma, United States
  • 297
    Germantown, Tennessee, United States
  • 260
    Austin, Texas, United States
  • 236
    Bedford, Texas, United States
  • 267
    Dallas, Texas, United States
  • 268
    Houston, Texas, United States
  • 211
    Layton, Utah, United States
  • 235
    Ogden, Utah, United States
  • 218
    Burlington, Vermont, United States
  • 279
    Danville, Virginia, United States
  • 277
    Charleston, West Virginia, United States
  • 213
    Marshfield, Wisconsin, United States
  • 400
    Chatswood, New South Wales, Australia
  • 404
    Adelaide, South Australia, Australia
  • 402
    Fitzroy, Victoria, Australia
  • 401
    Parkville, Victoria, Australia
  • 004
    Gent, Belgium
  • 003
    Kortrijk, Belgium
  • 205
    Calgary, Alberta, Canada
  • 203
    Edmonton, Alberta, Canada
  • 206
    Toronto, Ontario, Canada
  • 023
    Brno, Czechia
  • 020
    Litomysl, Czechia
  • 021
    Ostava, Czechia
  • 024
    Ostrava-Trebovice, Czechia
  • 026
    Praha 4, Czechia
  • 040
    Bethune, France
  • 041
    Toulouse Cedex 09, France
  • 055
    Berlin, Germany
  • 056
    Bernau, Germany
  • 054
    Bielefeld, Germany
  • 063
    Mainz, Germany
  • 051
    Munchen, Germany
  • 065
    Regensburg, Germany
  • 072
    Budapest, Hungary
  • 074
    Budapest, Hungary
  • 084
    Bergamo, Italy
  • 082
    Messina, Italy
  • 085
    Orbassano, Italy
  • 083
    Perugia, Italy
  • 080
    Pisa, Italy
  • 090
    Madrid, Spain
  • 100
    Goteborg, Sweden
  • 102
    Lund, Sweden
  • 101
    Stockholm, Sweden
09

References and documents

Publications

  • Markham A. Brivaracetam: First Global Approval. Drugs. 2016 Mar;76(4):517-22. doi: 10.1007/s40265-016-0555-6. PubMed 26899665 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2008, a primary completion of Mar 2017 and a completion of Mar 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2018, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2008
First posted
Sep 30, 2008
Start
Nov 2008
Primary completionActual
Mar 2017
CompletionActual
Mar 2017
Results first posted
Apr 23, 2018
Last update
Jul 11, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00761774
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Sep 30, 2008
Start date
Nov 2008
Primary completion
Mar 2017
Completion
Mar 2017
Results posted
Apr 23, 2018
Last update
Jul 11, 2018

Study contacts

UCB Cares
study director · +1 844 599 2273(UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivaracetam

Start the discussion